New Molecular Switch for Inborn Immunity Found

Researchers discover ANKIB1 enzyme is crucial for innate immune signaling and interferon production.

Published on Mar. 7, 2026

Got story updates? Submit your updates here. ›

An international team of researchers led by scientists from the University of Cologne have discovered that the enzyme ANKIB1 plays a crucial role in the process of innate immune signaling. The study reveals that ANKIB1 catalyzes a specific type of molecular modification called K11-ubiquitin, which acts as a docking platform to assemble the machinery that turns on type I and type III interferons, the body's frontline antiviral messengers. This finding solves a long-standing puzzle in innate immunity and provides opportunities for the future development of new therapies for various diseases.

Why it matters

The discovery of ANKIB1's role in innate immune signaling and interferon production has important implications for understanding and treating a variety of diseases. It provides a new target for modulating inflammatory and immune responses, which could be leveraged to enhance anti-tumor immunity or dampen excessive inflammation in autoimmune and neurodegenerative disorders.

The details

The researchers found that in the absence of ANKIB1, mice were unable to produce the interferons necessary to fight off a herpes simplex virus infection, leading to the death of the animals. Conversely, in a model of severe inflammatory disease, mice lacking ANKIB1 survived an otherwise lethal inflammation. These results demonstrate the essential role of ANKIB1 in regulating both physiologically required and pathological interferon responses.

  • The study 'Lysine 11-ubiquitination drives Type-I/III Interferon induction by cGAS–STING and Toll-Like Receptors 3 and 4' was published in Nature Cell Biology in 2026.

The players

Dr. Eva Rieser

A biochemist and immunologist at the Institute of Biochemistry of the University of Cologne's Faculty of Mathematics and Natural Sciences and a co-lead author of the study.

Professor Henning Walczak

The Alexander-von-Humboldt Professor of Biochemistry and Director of the Institute of Biochemistry I of the University of Cologne's Faculty of Medicine, a Principal Researcher at the CECAD Cluster of Excellence in Aging Research and the Cancer Institute of University College London, and a co-lead author of the study.

Professor Julian Pardo

A collaborator on the study from the Aragón Health Research Institute, CIBERINFEC and the University of Zaragoza, Spain.

Professor Antonio Alcamí

A collaborator on the study from the Center for Molecular Biology Severo Ochoa, Spanish National Research Council (CSIC), in Madrid, Spain.

Professor Brian Ferguson

A collaborator on the study from the University of Cambridge, UK.

Got photos? Submit your photos here. ›

What they’re saying

“We discovered that ANKIB1 decides when the alarm clock for immune cells sounds and, importantly, how loud this wake-up call will be.”

— Professor Henning Walczak, Alexander-von-Humboldt Professor of Biochemistry and Director of the Institute of Biochemistry I of the University of Cologne's Faculty of Medicine, Principal Researcher at the CECAD Cluster of Excellence in Aging Research and the Cancer Institute of University College London

“With K63- and M1-ubiquitin, so far only two letters of the ubiquitin signalling code were known. With the discovery of K11-ubiquitin as the third letter of the ubiquitin alphabet, we are now a decisive step closer to the deciphering of the ubiquitin code of cellular signalling.”

— Dr. Eva Rieser, Biochemist and immunologist at the Institute of Biochemistry of the University of Cologne's Faculty of Mathematics and Natural Sciences

“This level of mechanistic resolution, down to the exact ubiquitin chain type and the enzyme that generates it, is what turns a complex immune cascade into a concrete, druggable process.”

— Professor Henning Walczak, Alexander-von-Humboldt Professor of Biochemistry and Director of the Institute of Biochemistry I of the University of Cologne's Faculty of Medicine, Principal Researcher at the CECAD Cluster of Excellence in Aging Research and the Cancer Institute of University College London

What’s next

The researchers plan to further investigate how modulating ANKIB1 activity could be leveraged therapeutically to enhance antiviral or antitumor immunity, or to dampen excessive inflammation in autoimmune and neurodegenerative disorders.

The takeaway

The discovery of ANKIB1's role as a key regulator of innate immune signaling and interferon production provides a new target for the development of therapies to treat a variety of inflammatory, autoimmune, and neurodegenerative diseases, as well as to boost anti-cancer immunity.